CN111995508A - 一种抗肿瘤活性化合物Sanjoseolide的合成方法 - Google Patents
一种抗肿瘤活性化合物Sanjoseolide的合成方法 Download PDFInfo
- Publication number
- CN111995508A CN111995508A CN202010215285.6A CN202010215285A CN111995508A CN 111995508 A CN111995508 A CN 111995508A CN 202010215285 A CN202010215285 A CN 202010215285A CN 111995508 A CN111995508 A CN 111995508A
- Authority
- CN
- China
- Prior art keywords
- dihydroxy
- dimethoxymethyl
- methylbutyl
- sanjoseolide
- active compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PRVVZSLXJWSURQ-CSKARUKUSA-N (E)-1-[3-(2,3-dihydroxy-3-methylbutyl)-2,4-dihydroxyphenyl]-3-phenylprop-2-en-1-one Chemical compound CC(C)(O)C(O)Cc1c(O)ccc(C(=O)\C=C\c2ccccc2)c1O PRVVZSLXJWSURQ-CSKARUKUSA-N 0.000 title claims abstract description 41
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 16
- 238000001308 synthesis method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 22
- -1 2, 3-dihydroxy-3-methylbutyl Chemical group 0.000 claims abstract description 16
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000005513 chalcones Nutrition 0.000 claims abstract description 16
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims abstract description 16
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002243 precursor Substances 0.000 claims abstract description 13
- 229940125782 compound 2 Drugs 0.000 claims abstract description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000005882 aldol condensation reaction Methods 0.000 claims abstract description 5
- 230000002378 acidificating effect Effects 0.000 claims abstract description 3
- 239000003513 alkali Substances 0.000 claims abstract description 3
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 3
- 238000010189 synthetic method Methods 0.000 claims abstract description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims abstract 3
- 238000005805 hydroxylation reaction Methods 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical group [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000012043 crude product Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 4
- YUCBLVFHJWOYDN-HVLQGHBFSA-N 1,4-bis[(s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@H](OC=3C4=CC=CC=C4C(O[C@H]([C@@H]4N5CC[C@H]([C@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-HVLQGHBFSA-N 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 3
- 239000003054 catalyst Substances 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 2
- 239000012895 dilution Substances 0.000 claims 2
- 238000010791 quenching Methods 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 239000012069 chiral reagent Substances 0.000 claims 1
- 239000011259 mixed solution Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 13
- 238000003786 synthesis reaction Methods 0.000 abstract description 13
- 238000006257 total synthesis reaction Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000011734 sodium Substances 0.000 description 10
- 229940126214 compound 3 Drugs 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000005834 sharpless asymmetric dihydroxylation reaction Methods 0.000 description 3
- ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 2-methylpropan-2-ol;hydrate Chemical compound O.CC(C)(C)O ZQXSFZAMFNRZOQ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
- C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
本发明提供了一种抗肿瘤活性化合物Sanjoseolide的合成方法,包括如下工艺步骤:(1)将2,4‑二甲氧基甲基‑3‑异戊烯基苯乙酮通过Sharpless不对称双羟基化反应得到前体化合物2,4‑二甲氧基甲基‑3‑(2,3‑二羟基‑3‑甲基丁基)苯乙酮;(2)2,4‑二甲氧基甲基‑3‑(2,3‑二羟基‑3‑甲基丁基)苯乙酮和苯甲醛在碱的催化下发生羟醛缩合得到2,4‑二甲氧基甲基‑3‑(2,3‑二羟基‑3‑甲基丁基)查耳酮;(3)2,4‑二甲氧基甲基‑3‑(2,3‑二羟基‑3‑甲基丁基)查耳酮在酸性条件下脱保护基得到目标产物2,4‑二羟基‑3‑(2,3‑二羟基‑3‑甲基丁基)查耳酮。该工艺实现了Sanjoseolide的首次全合成,合成工艺简单,原料易得,收率高,工艺成本低。
Description
技术领域
本发明属于药物化学领域,涉及一种抗肿瘤活性化合物Sanjoseolide的合成方法。
背景技术
查耳酮类化合物结构简单,但是它表现出了显著的生物活性,一直以来是合成化学家们的首选目标。Sanjoseolide (参考文献:Shaffer, C, V,; Cai, S,; Peng, J,;Robles, A, J,; Hartley, R, M,; Powell, D, R,; Du, L,; Cichewicz, R, H,;Mooberry, S, L,J, Nat, Prod,2016, 79, 531−540)是2016年美国科学家从植物Dalea frutescens A, Gray (Leguminosae)中分离得到的一种天然化合物,其化合物名称为2,4-二羟基-3- (2,3-二羟基-3-甲基丁基)查耳酮,化学结构式如下所示:
Sanjoseolide表现出了较好的抗前列腺癌活性,特别是对人前列腺癌细胞PC-3和DU145的半抑制率IC50值分别是35μM和25.5μM,被认为是开发新型抗癌药物的重要先导化合物。尽管这一化合物的活性较好,但是不能从植物中大量分离得到,而且对于Sanjoseolide的全合成尚未报道,限制了Sanjoseolide作为抗癌药物的应用。
发明内容
本发明的目的在于针对现有技术无法实现Sanjoseolide人工合成的现状,提出一种Sanjoseolide的人工合成方法。
为此,本发明采用如下技术方案:
一种抗肿瘤活性化合物Sanjoseolide的合成方法,包括如下工艺步骤:
(1)将已知化合物2:2,4-二甲氧基甲基-3-异戊烯基苯乙酮通过Sharpless不对称双羟基化反应得到前体化合物3:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮;
(2)前体化合物3和苯甲醛在碱的催化下发生羟醛缩合得到前体化合物4:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮;
(3)前体化合物4在酸性条件下脱保护基得到目标产物:2,4-二羟基-3- (2,3-二羟基-3-甲基丁基)查耳酮。
所述化合物2的结构如下式所示:
所述化合物3的结构如下式所示:
所述化合物4的结构如下式所示:
本发明中,Sanjoseolide的全合成路线如图1所示。
本发明通过对Sanjoseolide (1)分子进行逆合成分析,设计了一条高效的合成路线,并成功的实现了这一合成策略,完成了Sanjoseolide (1)分子的合成。该合成策略主要包括两个关键反应,即AD-mix-β催化的Sharpless 不对称双羟化反应和羟醛缩合反应。Sharpless不对称双羟化反应主要用于构筑苯环侧链的“3-(2,3-二羟基-3-甲基丁基)”结构,而羟醛缩合是为了构筑查耳酮骨架。最后通过掉保护基完成Sanjoseolide的全合成。
本发明的有益效果在于:实现了Sanjoseolide的首次全合成;合成工艺简单,原料易得,收率高,工艺成本低;制得的Sanjoseolide 抗肿瘤活性好,为临床药物的开发创造了条件。
附图说明
图1为本发明Sanjoseolide的全合成路线;
图2为Sanjoseolide对两种癌细胞(RBE、HCCC-9810)的生长抑制率曲线。
具体实施方式
下面通过具体实施例对本发明方法进行进一步的说明。
仪器和试剂:所有有机溶剂在实验前必须做重蒸处理。化学药品均购买于阿拉丁,具有最高的商业纯度。使用200-300或300-400硅胶和反向硅胶对混合物进行分离纯化。玻璃仪器购买于欣维尔,在实验前晾干。表征包括核磁共振(德国Bruker),高分辨率电喷雾电离质谱(美国thermo scientific)和熔点仪(中国SGW X-4)。本发明用以下缩写形式解释核磁谱图和数据中质子的多重裂分性质:s=单重态,d=双重态,t=三重态,q=四重态,m=多重态。
实施例1
(1)前体化合物3:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮的合成
将AD-mix-β(2.22 g)加入到21 mL t-BuOH-H2O(V/V=1/1)溶液中, 室温下剧烈搅拌至明黄相间的两相, 在0 °C的冰水浴条件下加入甲基磺酰胺 (181 mg ,1.9 mmol), 然后迅速加入化合物2:2,4-二甲氧基甲基-3-异戊烯基苯乙酮 (488.5 mg,1.59 mmol), 在0 °C条件下继续剧烈搅拌,并通过TLC跟踪,反应48 h。反应结束后,加入饱和的硫代硫酸钠溶液淬灭反应,乙酸乙酯萃取三次(3 × 20 mL),饱和食盐水洗涤(20 mL),无水硫酸钠干燥,减压浓缩,粗产品经层析硅胶柱分离,得到前体化合物3的纯品239 mg,产率44%。
1H NMR (500 MHz, CDCl3) δ 7.57 (d, 1H, J= 10 Hz), δ 6.96 (d, 1H, J= 10Hz), δ 5.26 (s, 2H), δ 5.10 (d, 1H, J= 5 Hz), δ 5.00 (d, 2H, J= 5 Hz), δ 3.66(m, 1H), δ 3.59 (s, 3H), δ 3.49 (s, 3H), δ 3.18 (d, 1H, J= 10 Hz), δ 2.95 (m,2H), δ 2.55 (s, 3H), δ 1.32 (s, 3H), δ 1.29 (s, 3H); 13C NMR (125 MHz, CDCl3)δ 198.6, 159.1, 156.6, 130.0, 126.6, 123.0, 109.5, 101.9, 94.4, 78.2, 72.9,57.8, 56.5, 29.6, 26.7, 25.8, 23.6; HRMS(ESI) m/z 365.1577 [M + Na]+(C17H26O7Na的计算值为365.1576)。
(2)前体化合物4:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮的合成
加入化合物3 (150 mg, 0.44 mmol)和苯甲醛 (0.99 mL, 0.97 mmol)至5mL无水乙醇中,然后缓慢的加入固体氢氧化钾 (45 mg, 0.79 mmol)。在室温条件下反应24 h,然后加5mL水稀释反应,反应后溶液用乙酸乙酯萃取三次 (3 × 20 mL),饱和的食盐水洗涤 (20mL),无水硫酸钠干燥,减压浓缩。粗产品经层析硅胶柱分离,得到淡黄色油状化合物4的纯品160 mg,产率85%。
1H NMR (500MHz, CDCl3) δ 7.62 (d , 1H, J =15Hz), δ 7.55 (m, 2H), δ7.50 (d, 1H, J = 5 Hz), δ 7.35 (m, 3H), δ 7.23 (d, 1H, J = 5 Hz), δ 6.95 (d,1H, J = 5 Hz), δ 5.23 (d, 2H, J=0), δ 4.96 (dd, 2H, J =10 and 20 Hz), δ 3.47(s, 3H), δ 3.46 (s, 3H), δ 3.11 (d, 1H, J = 5 Hz), δ 3.00 (dd, 1H, J =5 and15 Hz), δ 2.90 (dd, 1H, J =15 and 15 Hz), δ 1.30 (s, 3H), δ 1.23 (s, 3H): 13CNMR (125MHz, CDCl3) δ 192.0, 158.9, 156.7, 144.3, 134.9, 130.7, 129.9, 129.1,128.6, 127.5, 126.5, 122.7, 109.9, 101.9, 94.6, 78.4, 73.1, 58.0, 56.6, 26.9,26.0, 23.8; HRMS(ESI) m/z 453.1891 [M + Na]+ (C24H30O7Na的计算值为453.1889)。
(3)目标产物Sanjoseolide的合成:
加入化合物4 (110.7 mg, 0.26 mmol)至甲醇 (3 mL)和THF (3 mL)混合液中,然后缓慢加入盐酸 (2.0 mol/L, 1.5 mL)。在55 °C 下反应 6 h,加水淬灭反应。乙酸乙酯萃取三次 (3 × 20 mL),饱和食盐水洗涤 (20 mL),无水硫酸钠干燥,减压浓缩。粗产品经层析硅胶柱分离,得到淡黄色粉末状Sanjoseolide纯品51.7 mg,产率58%。
1H NMR(500 MHz, CDCl3) δ 13.85 (s, -OH), δ 7.88 (d , 1H, J = 15 Hz), δ7.76 (d, 1H, J = 10 Hz), δ 7.65 (m, 2H), δ 7.60 (d, 2H, J = 15 Hz), δ 7.43(m, 3H), δ 6.54 (d, 1H, J = 10 Hz), δ 3.68 (dd, 1H, J =0 and 10 Hz), δ 3.25(dd, 1H, J = 0 and 15 Hz), δ 2.53 (dd, 1H, J =5 and 15 Hz), δ 1.39 (s, 3H), δ1.30 (s, 3H); 13C NMR (125MHz, CDCl3) δ 192.2, 164.3, 163.5, 144.3, 135.0,130.7, 130.0, 129.1, 128.7, 120.6, 113.8, 113.8, 109.4, 80.6, 73.7, 26.7,25.3, 22.8; HRMS(ESI) m/z 365.1367 [M + Na]+ C20H22O5Na的计算值为365.1365)。
实施例2
(1)前体化合物3:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮的合成
将AD-mix-β(0.7 g)加入到5 mL t-BuOH-H2O(V/V=1/1)溶液中, 室温下剧烈搅拌至明黄相间的两相, 在0 °C的冰水浴条件下加入甲基磺酰胺 (53.2mg ,0.56 mmol), 然后迅速加入化合物2:2,4-二甲氧基甲基-3-异戊烯基苯乙酮 (153.6 mg,0.5 mmol), 在0 °C条件下继续剧烈搅拌,并通过TLC跟踪,反应45 h。反应结束后,加入饱和的硫代硫酸钠溶液淬灭反应,乙酸乙酯萃取三次(3 × 20 mL),饱和食盐水洗涤(20 mL),无水硫酸钠干燥,减压浓缩,粗产品经层析硅胶柱分离,得到前体化合物3的纯品133 mg,产率78%。
1H NMR (500 MHz, CDCl3) δ 7.57 (d, 1H, J= 10 Hz), δ 6.96 (d, 1H, J=10 Hz), δ 5.26 (s, 2H), δ 5.10 (d, 1H, J= 5 Hz), δ 5.00 (d, 2H, J= 5 Hz), δ3.66 (m, 1H), δ3.59 (s, 3H), δ 3.49 (s, 3H), δ 3.18 (d, 1H, J= 10 Hz), δ 2.95(m, 2H), δ 2.55 (s, 3H), δ 1.32 (s, 3H), δ 1.29 (s, 3H); 13C NMR (125 MHz,CDCl3) δ 198.6, 159.1, 156.6, 130.0, 126.6, 123.0, 109.5, 101.9, 94.4, 78.2,72.9, 57.8, 56.5, 29.6, 26.7, 25.8, 23.6; HRMS(ESI) m/z 365.1577 [M + Na]+(C17H26O7Na的计算值为365.1576)。
(2)前体化合物4:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮的合成
把化合物3 (150 mg, 0.44 mmol) 和苯甲醛 (0.99 mL, 0.97 mmol)溶解在7 mL 的V(乙醇)∶V(水)=3∶2的乙醇溶液中, 然后缓慢加入30mg (0.53 mmol)的氢氧化钾,在室温下反应25h, 反应结束后, 加水稀释反应(5mL),乙酸乙酯萃取三次 (3 × 20 mL),饱和的食盐水洗涤 (20 mL),无水硫酸钠干燥,减压浓缩。粗产品经层析硅胶柱分离,得到淡黄色油状化合物4的纯品142 mg,产率75%。
1H NMR (500MHz, CDCl3) δ 7.62 (d , 1H, J =15Hz), δ 7.55 (m, 2H), δ7.50 (d, 1H, J = 5 Hz), δ 7.35 (m, 3H), δ 7.23 (d, 1H, J = 5 Hz), δ 6.95 (d,1H, J = 5 Hz), δ 5.23 (d, 2H, J=0), δ 4.96 (dd, 2H, J =10 and 20 Hz), δ 3.47(s, 3H), δ 3.46 (s, 3H), δ 3.11 (d, 1H, J = 5 Hz), δ 3.00 (dd, 1H, J =5 and15 Hz), δ 2.90 (dd, 1H, J =15 and 15 Hz), δ 1.30 (s, 3H), δ 1.23 (s, 3H): 13CNMR (125MHz, CDCl3) δ 192.0, 158.9, 156.7, 144.3, 134.9, 130.7, 129.9, 129.1,128.6, 127.5, 126.5, 122.7, 109.9, 101.9, 94.6, 78.4, 73.1, 58.0, 56.6, 26.9,26.0, 23.8; HRMS(ESI) m/z 453.1891 [M + Na]+ (C24H30O7Na的计算值为453.1889)。
(3)目标产物Sanjoseolide的合成:
加入化合物4 (369.8 mg, 0.86 mmol)至甲醇 (10 mL)和THF (10 mL)混合液中,然后缓慢加入盐酸 (2.0 mol/L, 5 mL)。在60 °C 下反应 5 h,加水淬灭反应。乙酸乙酯萃取三次 (3 × 50 mL),饱和的食盐水洗涤 (50 mL),无水硫酸钠干燥,减压浓缩。粗产品经层析硅胶柱分离,得到淡黄色粉末状Sanjoseolide纯品170 mg,产率57.8%。
1H NMR(500 MHz, CDCl3) δ 13.85 (s, -OH), δ 7.88 (d , 1H, J = 15 Hz),δ 7.76 (d, 1H, J = 10 Hz), δ 7.65 (m, 2H), δ 7.60 (d, 2H, J = 15 Hz), δ 7.43(m, 3H), δ 6.54 (d, 1H, J = 10 Hz), δ 3.68 (dd, 1H, J =0 and 10 Hz), δ 3.25(dd, 1H, J = 0 and 15 Hz), δ 2.53 (dd, 1H, J =5 and 15 Hz), δ 1.39 (s, 3H), δ1.30 (s, 3H); 13C NMR (125MHz, CDCl3) δ 192.2, 164.3, 163.5, 144.3, 135.0,130.7, 130.0, 129.1, 128.7, 120.6, 113.8, 113.8, 109.4, 80.6, 73.7, 26.7,25.3, 22.8; HRMS(ESI) m/z 365.1367 [M + Na]+ C20H22O5Na的计算值为365.1365)。
为进一步验证本发明得到的Sanjoseolide的生物活性,进行了实施例1目标产物Sanjoseolide对两种癌细胞(RBE、HCCC-9810)的生长抑制实验,其结果如下表所示:
表1: Sanjoseolide抑制癌细胞的IC50值
Sanjoseolide对两种癌细胞(RBE、HCCC-9810)的生长抑制率曲线如图2所示。实验表明,本发明制得的Sanjoseolide对癌细胞有着较强的抑制作用,表现出了较好的抗癌活性,能够用于抗癌药物的制备。
Claims (10)
1.一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,包括如下工艺步骤:
(1)将2,4-二甲氧基甲基-3-异戊烯基苯乙酮通过Sharpless不对称双羟基化反应得到前体化合物2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮;
(2)2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮和苯甲醛在碱的催化下发生羟醛缩合得到2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮;
(3)2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮在酸性条件下脱保护基得到目标产物2,4-二羟基-3- (2,3-二羟基-3-甲基丁基)查耳酮。
2.根据权利要求1所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(1)的具体过程如下:
以AD-mix-β为手性试剂,以t-BuOH-H2O溶液为溶剂,首先将二者混合,室温下剧烈搅拌为明黄相间的两相,在冰水浴条件下加入甲基磺酰胺,然后迅速加入2,4-二甲氧基甲基-3-异戊烯基苯乙酮,继续剧烈搅拌,反应45-50h;反应结束后,加入饱和硫代硫酸钠溶液淬灭反应,萃取,洗涤,干燥,减压浓缩,粗产品经层析硅胶柱分离,即得前体化合物2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮纯品。
3.根据权利要求1所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(2)的具体过程如下:
将2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮和苯甲醛加入至溶剂乙醇中,然后缓慢加入碱性催化剂,在室温条件下反应20-30 h,加水稀释反应,萃取,洗涤,干燥,减压浓缩,粗产品经层析硅胶柱分离,即得2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮纯品。
4.根据权利要求1所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(3)的具体过程如下:
将2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮加入作为溶剂的甲醇和四氢呋喃混合液中,然后缓慢加入盐酸溶液,在50-60°C 下反应 5-7 h,加水淬灭反应,萃取,洗涤,干燥,减压浓缩,粗产品经层析硅胶柱分离,即得目标产物2,4-二羟基-3- (2,3-二羟基-3-甲基丁基)查耳酮的纯品。
5. 根据权利要求2所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(1)中:2,4-二甲氧基甲基-3-异戊烯基苯乙酮、 AD-mix-β、t-BuOH-H2O和甲基磺酰胺的用量比为1 mmol:1.0-1.8g:10-15 mL:1.10-1.20 mmol。
6.根据权利要求3所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(2)中,所述碱性催化剂为氢氧化钾。
7.根据权利要求6所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(2)中:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮、苯甲醛、氢氧化钾和乙醇的用量比为1mmol:2.0-2.5mmol:1.5-2.0mmol:8-15mL。
8.根据权利要求3所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(2)加水稀释过程中,每mmol的2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)苯乙酮对应的加水量为10-15mL。
9.根据权利要求4所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(3)中:2,4-二甲氧基甲基-3- (2,3-二羟基-3-甲基丁基)查耳酮、甲醇、四氢呋喃、盐酸的用量比为1mmol:10.0-12.0mL:10.0-12.0mL: 10.0-12.0mmol 。
10.根据权利要求4所述的一种抗肿瘤活性化合物Sanjoseolide的合成方法,其特征在于,步骤(3)中:盐酸的浓度为1.8-2.2 mol/L。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010215285.6A CN111995508A (zh) | 2020-03-24 | 2020-03-24 | 一种抗肿瘤活性化合物Sanjoseolide的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010215285.6A CN111995508A (zh) | 2020-03-24 | 2020-03-24 | 一种抗肿瘤活性化合物Sanjoseolide的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111995508A true CN111995508A (zh) | 2020-11-27 |
Family
ID=73461775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010215285.6A Pending CN111995508A (zh) | 2020-03-24 | 2020-03-24 | 一种抗肿瘤活性化合物Sanjoseolide的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111995508A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041646A (zh) * | 2007-04-30 | 2007-09-26 | 浙江大学 | 含氮查耳酮衍生物的制备方法和用途 |
CN102701931A (zh) * | 2012-05-31 | 2012-10-03 | 北京工商大学 | 一种光学活性的3-羟基-2-辛酮的制备方法 |
CN105061366A (zh) * | 2015-09-11 | 2015-11-18 | 北京工商大学 | 一种光学活性2-甲基四氢呋喃-3-酮的制备方法 |
CN108047012A (zh) * | 2018-01-09 | 2018-05-18 | 宁夏大学 | 一种查尔酮sanjuanolide的合成方法 |
-
2020
- 2020-03-24 CN CN202010215285.6A patent/CN111995508A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041646A (zh) * | 2007-04-30 | 2007-09-26 | 浙江大学 | 含氮查耳酮衍生物的制备方法和用途 |
CN102701931A (zh) * | 2012-05-31 | 2012-10-03 | 北京工商大学 | 一种光学活性的3-羟基-2-辛酮的制备方法 |
CN105061366A (zh) * | 2015-09-11 | 2015-11-18 | 北京工商大学 | 一种光学活性2-甲基四氢呋喃-3-酮的制备方法 |
CN108047012A (zh) * | 2018-01-09 | 2018-05-18 | 宁夏大学 | 一种查尔酮sanjuanolide的合成方法 |
Non-Patent Citations (1)
Title |
---|
叶子平等: "天然产物Brosimacutins H和I 的对映选择性全合成", 《有机化学,CHIN. J. ORG. CHEM.》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106902880B (zh) | 4,6-二甲基-2-巯基嘧啶一价铜配合物在催化酮或醛氢转移反应制备醇中的应用 | |
CN115490697B (zh) | 一种手性氮杂螺[4,5]-癸胺的不对称合成方法 | |
CN114524795B (zh) | 一种改进的Rhodomyrtone制备方法 | |
CN111518006A (zh) | 25-羟基维生素D3和1α,25-二羟基维生素D3及其同位素内标化合物的制备方法 | |
CN111995508A (zh) | 一种抗肿瘤活性化合物Sanjoseolide的合成方法 | |
CN113354521B (zh) | 一种2-甲氧基-5-氟溴代苯乙酮的制备方法 | |
CN110698352A (zh) | 一种3-溴-5-氨基邻苯二酚二甲醚的合成方法 | |
CN115806543A (zh) | 一种盐酸阿替卡因中间体及其制备方法和应用 | |
CN110041161A (zh) | (3r)-2,4-二碘代-3-甲基丁-1-烯化合物及其制备方法和应用 | |
CN112321510A (zh) | 一种4-溴-5-甲基-1h-吲唑的制备方法 | |
CN113861034A (zh) | 2-氟-3-硝基苯甲酸的制备方法 | |
CN114751814B (zh) | 一种倍半萜类化合物的制备方法 | |
CN103508999A (zh) | 马沙骨化醇的合成中间体及其制备方法和用途 | |
CN114213261B (zh) | 一种4-甲氧基-2-硝基苯胺的制备方法 | |
CN111170886B (zh) | 一种地佐辛杂质的制备方法 | |
CN108997117A (zh) | 一种制备4-乙酰氧基-2-甲基-2-丁烯醛的新方法 | |
CN114907212B (zh) | 一种维生素a中间体的制备方法 | |
CN114957284B (zh) | 天然产物Lycibarbarine的高效合成方法及应用 | |
CN114605483B (zh) | 一种淫羊藿次苷ⅰ的制备工艺 | |
CN110256210B (zh) | 一种1,2,3-三甲氧基-4-苄基苯的制备方法 | |
CN110452097B (zh) | 一种1-羟基芘的制备方法 | |
CN114085130B (zh) | ((1r,8s,9s,z)-双环[6.1.0]非-4-烯-9-基)甲醇的合成方法 | |
CN114044762B (zh) | 一种氯美扎酮中间体的制备方法 | |
CN110028437B (zh) | 一种微波促进制备2-苯基-3-醛基吲哚类化合物的方法 | |
CN116514633A (zh) | 一种3,3'-(蒽-9,10-二基)二丙酸的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201127 |